Financials NewGLAB Pharma CO.,LTD

Equities

A214870

KR7214870008

Phones & Handheld Devices

End-of-day quote Korea S.E. 06:00:00 2023-03-08 pm EST 5-day change 1st Jan Change
1,383 KRW -27.44% Intraday chart for NewGLAB Pharma CO.,LTD -.--% -.--%

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 66,154 278,782 384,364 355,975 370,576 45,813
Enterprise Value (EV) 1 53,681 275,055 398,522 370,556 397,258 78,231
P/E ratio -8.98 x -88.3 x -15.8 x -6.92 x -5.2 x 23 x
Yield - - - - - -
Capitalization / Revenue 3.55 x 2.91 x 7.06 x 12.1 x 17.1 x 3.63 x
EV / Revenue 2.88 x 2.87 x 7.32 x 12.6 x 18.3 x 6.2 x
EV / EBITDA -11.2 x 244 x -26.9 x -14.7 x -6.86 x 12.7 x
EV / FCF -8.79 x -8.3 x -13.9 x 16.2 x -17.3 x -47.9 x
FCF Yield -11.4% -12% -7.21% 6.19% -5.78% -2.09%
Price to Book 2.08 x 4.15 x 6.07 x 12.3 x -19.5 x -2.62 x
Nbr of stocks (in thousands) 14,555 24,781 29,229 30,954 32,365 33,126
Reference price 2 4,545 11,250 13,150 11,500 11,450 1,383
Announcement Date 3/20/19 2/27/20 3/11/21 3/17/22 3/14/23 3/21/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 18,640 95,820 54,417 29,354 21,711 12,621
EBITDA 1 -4,813 1,129 -14,799 -25,272 -57,887 6,181
EBIT 1 -5,812 481.8 -17,711 -29,906 -61,449 5,214
Operating Margin -31.18% 0.5% -32.55% -101.88% -283.04% 41.31%
Earnings before Tax (EBT) 1 -7,763 -2,741 -23,444 -53,879 -74,389 -29.35
Net income 1 -7,362 -2,690 -22,609 -50,511 -69,550 1,991
Net margin -39.5% -2.81% -41.55% -172.08% -320.35% 15.78%
EPS 2 -506.4 -127.4 -834.3 -1,662 -2,201 60.12
Free Cash Flow 1 -6,104 -33,131 -28,726 22,921 -22,978 -1,633
FCF margin -32.75% -34.58% -52.79% 78.08% -105.84% -12.94%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/20/19 2/27/20 3/11/21 3/17/22 3/14/23 3/21/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - 14,158 14,581 26,682 32,418
Net Cash position 1 12,473 3,727 - - - -
Leverage (Debt/EBITDA) - - -0.9567 x -0.577 x -0.4609 x 5.245 x
Free Cash Flow 1 -6,104 -33,131 -28,726 22,921 -22,978 -1,633
ROE (net income / shareholders' equity) -21.1% -5.44% -35% -112% -1,758% -4.37%
ROA (Net income/ Total Assets) -5.5% 0.34% -9.07% -15.5% -53.4% 10.8%
Assets 1 133,867 -791,721 249,403 325,380 130,138 18,390
Book Value Per Share 2 2,184 2,710 2,166 934.0 -587.0 -528.0
Cash Flow per Share 2 1,017 1,743 1,507 1,062 207.0 15.80
Capex 1 130 150 193 1,257 1,091 415
Capex / Sales 0.7% 0.16% 0.35% 4.28% 5.03% 3.29%
Announcement Date 3/20/19 2/27/20 3/11/21 3/17/22 3/14/23 3/21/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Equities
  3. A214870 Stock
  4. Financials NewGLAB Pharma CO.,LTD